-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Hold" at StockNews.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Hold" at StockNews.com
StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) from a sell rating to a hold rating in a report published on Monday morning.
Separately, Piper Sandler initiated coverage on Lexicon Pharmaceuticals in a research note on Friday, August 12th. They issued an overweight rating and a $10.00 target price on the stock.
Get Lexicon Pharmaceuticals alerts:Lexicon Pharmaceuticals Stock Down 4.1 %
Shares of LXRX opened at $2.13 on Monday. Lexicon Pharmaceuticals has a 52 week low of $1.31 and a 52 week high of $5.22. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $401.99 million, a price-to-earnings ratio of -3.44 and a beta of 1.36. The stock's 50-day moving average price is $2.24 and its 200-day moving average price is $2.32.
Institutional Trading of Lexicon Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Bank of Montreal Can acquired a new position in Lexicon Pharmaceuticals in the 1st quarter worth about $26,000. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $32,000. The Manufacturers Life Insurance Company acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $38,000. Tower Research Capital LLC TRC raised its holdings in Lexicon Pharmaceuticals by 214.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 19,389 shares of the biopharmaceutical company's stock worth $46,000 after purchasing an additional 13,232 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in Lexicon Pharmaceuticals by 76.8% in the 3rd quarter. Victory Capital Management Inc. now owns 20,433 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 8,873 shares during the period.About Lexicon Pharmaceuticals
(Get Rating)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
Further Reading
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) from a sell rating to a hold rating in a report published on Monday morning.
斯托克新聞網在週一上午發佈的一份報告中將Licion PharmPharmticals(納斯達克代碼：LXRX-GET Rating)的股票評級從賣出上調至持有。
Separately, Piper Sandler initiated coverage on Lexicon Pharmaceuticals in a research note on Friday, August 12th. They issued an overweight rating and a $10.00 target price on the stock.
另外，派珀·桑德勒在8月12日星期五的一份研究報告中對Licion PharmPharmticals進行了報道。他們對該股發佈了增持評級和10.00美元的目標價。
Lexicon Pharmaceuticals Stock Down 4.1 %
Licion製藥類股下跌4.1%
Shares of LXRX opened at $2.13 on Monday. Lexicon Pharmaceuticals has a 52 week low of $1.31 and a 52 week high of $5.22. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $401.99 million, a price-to-earnings ratio of -3.44 and a beta of 1.36. The stock's 50-day moving average price is $2.24 and its 200-day moving average price is $2.32.
週一，LXRX的股價開盤報2.13美元。Licion PharmPharmticals的52周低點為1.31美元，52周高位為5.22美元。該公司的速動比率為7.54，流動比率為7.54，債務權益比率為0.17。該公司市值為4.0199億美元，市盈率為-3.44倍，貝塔係數為1.36。該股的50日移動均線價格為2.24美元，200日移動均線價格為2.32美元。
Institutional Trading of Lexicon Pharmaceuticals
Licion製藥的機構性交易
About Lexicon Pharmaceuticals
關於Licion製藥公司
(Get Rating)
(獲取評級)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
Licion製藥公司是一家生物製藥公司，專注於藥品的發現、開發和商業化。該公司正在開發的口服小分子藥物候選藥物包括用於治療心力衰竭和1型糖尿病的已完成第三階段臨牀試驗的索他利氟秦；以及用於治療神經病理性疼痛的LX9211。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- 免費獲取StockNews.com關於Licion PharmPharmticals(LXRX)的研究報告
- 三隻CBD股票將主宰一個萌芽行業
- 機構對ADI的支持仍然很高
- 60/40的投資組合組合還在《時尚》雜誌上流行嗎？
- 微軟股票：是時候備份卡車了嗎？
- Salesforce裁員，儘管面臨挑戰，但收入強勁
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Licion PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Licion製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧